ARMO BioSciences priced its initial public offering of 7,529,412 shares of its common stock at a price to the public of $17.00 per share for total gross proceeds of approximately $128.0 million.
Friday, January 26, 2018
ARMO BioSciences (ARMO) began trading on the Nasdaq on Fri 26 Jan 18
ARMO BioSciences is a late-stage immuno-oncology company that is developing a pipeline of novel, proprietary product candidates designed to activate the immune system of cancer patients to recognize and eradicate tumors.
ARMO BioSciences priced its initial public offering of 7,529,412 shares of its common stock at a price to the public of $17.00 per share for total gross proceeds of approximately $128.0 million.
ARMO BioSciences priced its initial public offering of 7,529,412 shares of its common stock at a price to the public of $17.00 per share for total gross proceeds of approximately $128.0 million.
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment